Fulgent Historical Balance Sheet
FLGT Stock | USD 20.24 0.11 0.55% |
Trend analysis of Fulgent Genetics balance sheet accounts such as Total Current Liabilities of 49.4 M or Total Stockholder Equity of 1.2 B provides information on Fulgent Genetics' total assets, liabilities, and equity, which is the actual value of Fulgent Genetics to its prevalent stockholders. By breaking down trends over time using Fulgent Genetics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Fulgent Genetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Fulgent Genetics is a good buy for the upcoming year.
Fulgent Genetics Inventory |
|
Fulgent |
About Fulgent Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Fulgent Genetics at a specified time, usually calculated after every quarter, six months, or one year. Fulgent Genetics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Fulgent Genetics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Fulgent currently owns. An asset can also be divided into two categories, current and non-current.
Fulgent Genetics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Fulgent Genetics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Fulgent Genetics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Fulgent Genetics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Fulgent Genetics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Cash
Cash refers to the most liquid asset of Fulgent Genetics, which is listed under current asset account on Fulgent Genetics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Fulgent Genetics customers. The amounts must be unrestricted with restricted cash listed in a different Fulgent Genetics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Most accounts from Fulgent Genetics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Fulgent Genetics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulgent Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Fulgent Stock please use our How to Invest in Fulgent Genetics guide.At this time, Fulgent Genetics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Other Current Assets is likely to gain to about 27.6 M in 2024, whereas Accounts Payable is likely to drop slightly above 10.3 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 28.4M | 24.2M | 26.9M | 28.3M | Total Assets | 1.3B | 1.4B | 1.2B | 1.3B |
Fulgent Genetics balance sheet Correlations
Click cells to compare fundamentals
Fulgent Genetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fulgent Genetics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 88.8M | 700.5M | 1.3B | 1.4B | 1.2B | 1.3B | |
Other Current Liab | 3.6M | 35.0M | 28.4M | 24.2M | 26.9M | 28.3M | |
Total Current Liabilities | 6.0M | 131.1M | 112.8M | 116.2M | 73.0M | 49.4M | |
Total Stockholder Equity | 82.8M | 569.4M | 1.2B | 1.3B | 1.1B | 1.2B | |
Net Tangible Assets | 82.8M | 569.4M | 1.2B | 973.0M | 1.1B | 1.2B | |
Property Plant And Equipment Net | 6.0M | 40.2M | 62.3M | 81.4M | 95.6M | 100.4M | |
Net Debt | (9.3M) | (71.6M) | (143.6M) | (58.9M) | (82.2M) | (78.1M) | |
Retained Earnings | (63.4M) | 150.9M | 657.6M | 801M | 633.2M | 664.8M | |
Accounts Payable | 1.6M | 26.5M | 20.5M | 23.1M | 15.4M | 10.3M | |
Cash | 12.0M | 87.4M | 164.9M | 79.5M | 97.5M | 50.9M | |
Non Current Assets Total | 12.0M | 84.7M | 204.3M | 480.4M | 727.5M | 763.9M | |
Non Currrent Assets Other | (36.8M) | (88.0M) | 142.0M | (287.4M) | 22.7M | 23.9M | |
Other Assets | 251K | 44.5M | 912.6M | 26.6M | 1.0 | 0.95 | |
Cash And Short Term Investments | 70.2M | 431.9M | 935.5M | 852.9M | 424.2M | 312.5M | |
Net Receivables | 6.6M | 204.1M | 143.3M | 52.7M | 57.4M | 52.9M | |
Common Stock Shares Outstanding | 18.7M | 24.1M | 31.0M | 31.0M | 29.8M | 23.5M | |
Liabilities And Stockholders Equity | 88.8M | 700.5M | 1.3B | 1.4B | 1.2B | 1.3B | |
Inventory | 277K | 16.5M | 12.2M | 4.3M | 5.8M | 4.4M | |
Other Current Assets | 277K | 3.7M | 6.0M | 44.5M | 26.2M | 27.6M | |
Other Stockholder Equity | 146.1M | 418.1M | 501.9M | 486.6M | 501.7M | 263.1M | |
Total Liab | 6.0M | 131.1M | 112.8M | 116.2M | 102.0M | 52.6M | |
Property Plant And Equipment Gross | 8.6M | 41.0M | 81.9M | 124.6M | 135.1M | 141.9M | |
Total Current Assets | 76.8M | 615.7M | 1.1B | 905.6M | 507.8M | 365.6M | |
Accumulated Other Comprehensive Income | 146K | 438K | (759K) | (20.9M) | 1.2M | 1.3M | |
Property Plant Equipment | 8.6M | 40.2M | 62.3M | 98.9M | 113.8M | 119.4M | |
Retained Earnings Total Equity | (63.0M) | (63.4M) | 150.9M | 657.6M | 756.2M | 794.0M | |
Short Term Investments | 58.3M | 344.4M | 770.7M | 773.4M | 326.7M | 326.9M | |
Non Current Liabilities Total | 2.3M | 959K | 7.5M | 28.1M | 29.0M | 30.5M | |
Capital Surpluse | 114.2M | 146.1M | 418.1M | 501.9M | 577.2M | 606.1M | |
Long Term Investments | 42.8M | 132.5M | 507.0M | 339.0M | 444.0M | 466.2M | |
Non Current Liabilities Other | 2.3M | 959K | 7.5M | 28.1M | 11.0M | 6.8M | |
Net Invested Capital | 82.8M | 584.4M | 1.2B | 1.3B | 1.1B | 688.3M | |
Net Working Capital | 33.4M | 393.5M | 961.6M | 539.8M | 434.8M | 381.8M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.